Genmab and J&J 'love' partnership as some ponder takeover
LONDON (Reuters) – Genmab was Europe’s second biggest biotech company, until its partner Johnson & Johnson bought Switzerland’s Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot. Source: Reuters Medical News